Gallium-68 PSMA-11

Diagnostic / Nuclear Medicine

Also known as: 68Ga-PSMA-11, Ga-68 PSMA-11, Gallium PSMA, Illuccix, Locametz

PSMA Imaging AgentsResearch phase: ApprovedRegulatory: FDA-approved 2020 (UCLA/UCSF) and 2021 (Illuccix, Locametz) for PET imaging in prostate cancer.

Mechanism

Gallium-68 PSMA-11 is an FDA-approved PET imaging agent for prostate cancer. It detects the PSMA protein overexpressed on prostate cancer cells.

Technical detail

Gallium-68 PSMA-11 is a radiolabeled urea-based inhibitor of prostate-specific membrane antigen (PSMA/FOLH1) chelated with 68Ga for PET/CT imaging. It detects PSMA-expressing prostate cancer with high sensitivity for biochemical recurrence and initial staging. Particularly valuable for identifying oligometastatic disease amenable to targeted therapy.

Evidence

Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study).
Cerci et al. (2022) — J Nucl Med — PMID: 34215674
Prospective multicenter study across 17 centers found 68Ga-PSMA-11 PET/CT improved recurrence localization and clinical decision-making in biochemical recurrence after radical therapy when conventional imaging was negative, supporting its practical diagnostic value in relapsed prostate cancer.
moderate

Build a personalized protocol with Gallium-68 PSMA-11 →